This technical application poster, originally showcased at ISCT 2024, shares data demonstrating the development of a natural killer (NK) cell expansion system that enables genetic customization and clinical scale manufacturing. The NK cell gene delivery was optimized using a lentiviral vector (LVV) and NK cell expansion was optimized using a combination of static (G Rex) and stirred tank reactors (STR).
NK cells are innate immunity experts at identifying and destroying abnormal cells in an antigen independent manner. This recognition system has positioned NK and Chimeric Antigen Receptor (CAR) NK cells as a promising new solution for the cancer immunotherapy field, as they address shortcomings experienced by T cell and CAR T based therapies, increased feasibility as an off the shelf product, improved safety profile, and greater potential in solid tumor settings. However, NK cells have been historically difficult to genetically modify, with unpredictable expansion due to multiple factors including donor variation.
Download this poster to learn how we can help streamline your NK program journey to market.
About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.
